Toronto-based generic, biosimilar and consumer-health pharmaceutical maker, the largest Canadian-headquartered pharma company, recently listed on the TSX.
Toronto-based generic, biosimilar and consumer-health pharmaceutical maker, the largest Canadian-headquartered pharma company, recently listed on the TSX.
In one line: Canada's Teva/Viatris.
Moat: narrow (scale, regulatory licence). Largest Canadian pharma manufacturing scale and a broad portfolio of regulatory-approved generic/biosimilar filings.
Headquarters: Toronto, Canada · Founded: 1974 · Employees: 6,216
Size Apotex Health (APTX.TO) is a Canada Health Care company (Pharmaceuticals: Major) with a market value of $6.56B, the 95th largest of 405 Canada companies the cockpit tracks. Shares closed at C$41.17 on 18 Nov 2026.
Growth Revenue grew 4.2% over the last twelve months (peer median +16.4%); the operating margin is 32.0% (peer median 13.8%).
Valuation It trades at 19.3× forward earnings against a peer median of 24.1× (7th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 19.9 points above its cost of capital (5.1% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | C$3.49B | C$3.35B | C$2.94B |
| Revenue growth | — | +4% | +14% | — |
| Gross profit | n/a | C$1.83B | C$1.70B | C$1.05B |
| EBITDA | n/a | C$1.27B | C$1.13B | C$563M |
| Net income | n/a | C$374M | C$152M | -C$147M |
| Free cash flow | n/a | C$520M | C$461M | C$475M |
| Capital expenditure | n/a | C$182M | C$244M | C$112M |
| Total debt | C$2.94B | C$3.52B | C$2.65B | C$1.87B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Apotex Health APTX.TO | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | APTX.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.7% | -2.1% | highest of 21 |
| Distance from 52-week high | -0.1% | -25.4% | highest of 21 |
| Revenue growth (TTM) | +4.2% | +16.4% | 5th lowest of 18 |
| Operating margin | 32.0% | 13.8% | 3rd highest of 19 |
| Forward P/E | 19.3× | 24.1× | 7th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -11.9% | 7.1% | least demanding of 11 |
| Growth delivered (Del g) | +4.2% | +12.3% | lowest of 11 |
| Hurdle (Req g minus delivered) | -16.1 pp | -8.4 pp | 5th least demanding of 11 |
| ROIC minus cost of capital | +19.9 pp | +1.9 pp | 4th highest of 18 |
| EV / EBITDA | 9.7× | 25.5× | 2nd cheapest of 10 |
| Net debt / EBITDA | 2.3× | 0.3× | 3rd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 10.8× | 1.1% | +303.3% |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 24.4× | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |